Faegre Baker Daniels guided Endocyte, Inc. on its $86.2 million shelf-takedown offering of 20,535,714 shares of common stock, which includes full exercise of the underwriters’ greenshoe option.
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. Endocyte is also advancing its adaptor-controlled CAR T-cell therapy into the clinic in 2018, where it will be studied in osteosarcoma. The shares trade on the NASDAQ Global Market under the symbol "ECYT." Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc. acted as joint book-running managers for the offering. Wedbush Securities Inc. acted as co-lead manager for the offering.
Dan Boeglin, Jon Zimmerman, Christine Long, Ryan Woessner and Sarah Bartlett led the deal team for the offering. Faegre Baker Daniels has represented Endocyte since 2009.
Please see Endocyte's press release for more information about the offering.